– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3’25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended September 30, 2025, and provided...

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025; expected to be sufficient to fund operations into Q4 of 2027CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFRm NSCLC,” said Mark Velleca, M.D., Ph.D.,...

VONORE, Tenn., Nov. 06, 2025 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2026 first quarter ended September 28, 2025. The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments. Overview:Net sales for the first quarter were $69.0 million, up $3.6 million, or 5.6%, from the comparable prior-year period Income from continuing operations was $3.7 million, or $0.22 per diluted share, up from $1.0 million, or $0.06 per diluted share, in the prior-year period Adjusted Net Income, a non-GAAP measure, was $4.5 million, or $0.28 per diluted share, up from $1.9 million, or $0.12 per diluted share, in the prior-year period Adjusted EBITDA, a non-GAAP measure, was $6.7 million, up $2.9...

Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash Flow GRAPEVINE, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and nine months ended September 30, 2025. “The third quarter was challenging, reflecting continued pressure on consumer demand while we rebuild retail relationships and work through excess retailer inventory primarily within our Solo Stove division.” said John Larson, President and Chief Executive Officer. “We maintained stable gross margins and generated...

– $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) – – Aligned with U.S. FDA on Registrational Path for Zervimesine – – Expanded Access Program for Dementia with Lewy Bodies Ongoing – PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine (CT1812),” stated Lisa Ricciardi, Cognition’s president and CEO. “The alignment we achieved with the FDA on a registrational...

LOWELL, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 3, 2025. Fourth Quarter Fiscal Year 2025 GAAP ResultsRevenue was $261.2 million, an increase of 30.1%, compared to $200.7 million in the previous year fiscal fourth quarter and an increase of 3.6% compared to $252.1 million in the prior fiscal quarter; Gross margin was 54.5%, compared to 54.7% in the previous year fiscal fourth quarter and 55.3% in the prior fiscal quarter; Income from operations was $39.6 million, or 15.2% of revenue, compared to income from operations of $27.5 million, or 13.7% of revenue, in the previous year fiscal fourth quarter and income from operations...

Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS® remains the number one cannabis brand1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 third quarter business results. “Our third quarter results reflect continued progress towards our objectives, with the business reaching record levels of net revenue, gross profit and adjusted EBITDA generation, driven by the seventh consecutive quarter of record net revenue at Cronos Israel, as well as by continued...

IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors  Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2025, and recent business highlights. “We have made exciting progress during 2025 advancing our pipeline of next generation therapeutics for solid tumors toward the clinic,” said Joshua Brumm, chief executive officer of Crescent. “For CR-001, our PD-1 x VEGF bispecific antibody,...

Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3-25 Highlights Financial resultsRevenues were $121,548, an increase of $29,285 or 32% over the same period in prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo Transactions and the growth of our key promoted products. Gross margin was $55,810 or 46%...

TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025.Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-year Underlying revenue reflects continued growth in the Education segment, a consistent rate of decline in the SET segment, and a modest decline in the ETM segment Q3 adjusted SG&A decline of 9.7% reflects increased momentum on structural and demand-driven expense optimization initiatives, including legacy acquisition integration, technology modernization, and process efficiencies Q3 operating loss of $102.1 million including $102.0 million of non-cash goodwill impairment...